Zacks Investment Research on MSN14d
United Therapeutics Stock Down Despite Q4 Earnings & Sales BeatUnited Therapeutics’ UTHR fourth-quarter 2024 earnings of $6.19 per share beat the Zacks Consensus Estimate of $6.10. Earnings rose 42% year over year on the back of higher product sales. See the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback